Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) dropped 6.7% during trading on Tuesday . The company traded as low as $3.33 and last traded at $3.36, with a volume of 53,436 shares trading hands. The stock had previously closed at $3.60.

AUPH has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th. Leerink Swann restated an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $7.15.

The stock’s market capitalization is $112.97 million. The stock has a 50 day moving average of $2.96 and a 200-day moving average of $2.69.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.